China Will Expand Clinical Trial Requirements, Emphasizing Higher-Risk Devices
This article was originally published in The Gray Sheet
Executive Summary
China’s FDA will require clinical trials for medical devices with higher risks, and mandate a clinical trial review and approval process prior to study starts for class 3 products. Industry advisors worry that product launch delays will result, particularly for implants.